Extension and structural variability of the antithrombin-binding sequence in heparin. J Biol Chem. 1984;259(20):12368-12376. 17. Nesheim ME. A simple rate law that describes the kinetics of the heparin-catalyzed reaction between antithrombin III and thrombin. J Biol Chem. 1983;258(23):14708-14717. 18. Oosta GM, Gardner WT, Beeler DL, Rosenberg RD. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci U S A. 1981;78(2):829-833. 19. B guin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost. 1988;60(3):457-462. 20. Blajchman MA, Young E, Ofosu FA. Effects of unfraction- ated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann N Y Acad Sci. 1989;556:245-254. 21. Ofosu FA, Sie P, Modi GJ, et al. The inhibition of throm- bin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J. 1987;243(2):579-588. 22. Eika C. Inhibition of thrombin induced aggregation of human platelets by heparin. Scand J Haematol. 1971;8(3): 216-222. 23. Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol. 1980;17(4):259-291. 24. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on plate- let aggregation. J Clin Invest. 1980;65(1):64-73. 25. Heiden D, Mielke CH Jr, Rodvien R. Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release. Br J Haematol. 1977;36(3):427-436. 26. Fernandez F, N guyen P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res. 1986;43(4):491-495. 27. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anti- coagulant therapy in the treatment of proximal-vein throm- bosis. N Engl J Med. 1982;307(27):1676-1681. 28. Castellot JJ Jr, Favreau LV, Karnovsky MJ, Rosenberg RD. Inhibition of vascular smooth muscle cell growth by endo- thelial cell-derived heparin. 